...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.

,,hummmmm,,it is becoming ever increasingly more plausible and believable that our science is leading edge!,,if so,,,, what is our library of molecules worth to BP with a similar business interest?..would they not want to obtain such a vast pipeline??..hardly imo,,..this technology has to be worth,,can we say ,, many Billions!!!,,

Share
New Message
Please login to post a reply